List view / Grid view
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
A pioneering team of scientists from Rice University has discovered that a particular combination of chemotherapeutics, including mitocans that target mitochondria, form a powerful treatment for acute myeloid leukaemia patients.
The involvement of clathrin in the development of liver cancer has been described for the first time, which could lead to more targeted therapy.
A new algorithm has been developed which personalises which cancer mutations are best targets for immunotherapy.
A study has demonstrated that blocking certain receptors in mice reduced Ewing sarcoma growth and metastasis, which could be used within future treatments.
Researchers have used whole genome sequencing to analyse breast cancers and reveal which are more responsive to treatments, which could improve the development of oncologic therapies.
A method designed to genetically alter laboratory mice can also be used to produce personalised animal models of an aggressive type of malignant brain cancer in children.
CRISPR is the buzzword of the moment in the drug discovery industry – mainly due to its potential to correct disease-causing mutations. However, those using the technology need to be mindful that it is used responsibly, and possible risks are considered before use. Mark Behlke discusses the potential of CRISPR…
Researchers have successfully created a multi-organ in vitro model to test toxicity and efficacy of drugs.
Researchers have, for the first time, duplicated a patient's blood-brain barrier (BBB), creating a human BBB chip with stem cells.
Researchers have found 12 genes which cause MS, creating potential for preventative treatment of the condition.
ZYNTEGLO™ is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT).
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
Researchers have shown how skin vaccinations could be used as a vaccination strategy for sexually transmitted infections (STIs).
Comprehensive tumour profiling promises new therapeutic options for patients with advanced cancer.
